Indications
Teduglutide Viatris is indicated for the treatment of patients 4 months corrected gestational age and above with Short Bowel Syndrome (SBS). Patients should be stable following a period of intestinal adaptation after surgery.
Composition
- Active substance
- teduglutide
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Teduglutide Viatris
- Active substance
- teduglutide
- ATC code
- A16AX08
- Therapeutic area
- Short Bowel Syndrome
- Marketing authorisation holder
- Viatris Limited
- Status
- Authorised